Internal Medicine, Hematology & Oncology · Dallas, TX
NPI
1861443483
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
7777 Forest Ln, C-648
Dallas, TX, 75230
Phone (972) 566-2622
Groups this clinician bills Medicare through
Medicare paid, 2024
$19K
360 services
Medicare patients, 2024
19
Average age 65
Drug cost, 2024
$1.1M
617 prescriptions
Company payments, 2025
$606
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Virginia I Stark-Vance was code 99214 (office e&m - established), 22 times for 12 patients. In total Virginia I Stark-Vance billed 360 services in 32 codes, and Medicare paid $19K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-10-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 22 | 12 | $98.55 | $2,168 |
By year: 2022 $26K for 2,900 services; 2023 $37K for 4,034 services; 2024 $19K for 360 services.
Medicare prescription drug claims, 2024
In 2024, the drug Virginia I Stark-Vance prescribed most often to Medicare patients was Oxycodone Hcl, with 33 prescriptions and refills. In total Virginia I Stark-Vance wrote 617 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone Hcl Generic | 33 | 33 | Under 11 | $2,411 |
| Levetiracetam Generic | 20 | 41 | Under 11 | $390 |
| Alprazolam Generic | 19 | 19 | Under 11 | $63.47 |
| Lacosamide Generic | 19 | 19 | Under 11 | $462 |
| Diazepam Generic | 18 | 18 | Under 11 | $260 |
| Trazodone Hcl Generic | 17 | 45 | Under 11 | $194 |
| Jakafi Ruxolitinib Phosphate | 14 | 14 | Under 11 | $238K |
| Eliquis Apixaban | 13 | 13 | Under 11 | $6,428 |
| Clonazepam Generic | 13 | 24 | Under 11 | $359 |
| Zirabev Bevacizumab-Bvzr | 13 | 13 | Under 11 | $127K |
| Metformin Hcl Generic | 12 | 12 | Under 11 | $22.87 |
| Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine | 12 | 12 | Under 11 | $262 |
| Pomalyst Pomalidomide | 12 | 12 | Under 11 | $277K |
| Simvastatin Generic | 12 | 22 | Under 11 | $177 |
| Hydroxyurea Generic | 12 | 36 | Under 11 | $575 |
Brand drugs: - claims; generic drugs: 498 claims; opioid claims: 70.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Virginia I Stark-Vance $606 ($606 in general payments such as food, travel and fees) from 12 companies. The largest payer was Sobi, Inc with $125.
| Company | Payments | Amount |
|---|---|---|
| Sobi, Inc SOBI.ST | 2 | $125 |
| Janssen Biotech, Inc. JNJ | 5 | $120 |
| Genentech USA, Inc. ROG.SW | 1 | $120 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $57.39 |
| Eisai Inc. 4523.T | 2 | $41.08 |
| Immunocore Limited IMCR | 1 | $30.75 |
| Incyte Corporation INCY | 1 | $24.84 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $22.93 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22.32 |
| Array Biopharma Inc PFE | 1 | $15.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.